Your browser doesn't support javascript.
loading
In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013.
Liu, Hui; Yang, Heng-lin; Tang, Lin-hua; Li, Xing-liang; Huang, Fang; Wang, Jia-zhi; Li, Chun-fu; Wang, Heng-ye; Nie, Ren-hua; Guo, Xiang-rui; Lin, Ying-xue; Li, Mei; Wang, Jian; Xu, Jian-wei.
Afiliação
  • Liu H; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. liubible@
  • Yang HL; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. yang_heng
  • Tang LH; National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, PR China. ipdtlh@sh163.net.
  • Li XL; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. lxl5451@y
  • Huang F; National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, PR China. ipdhuangfang@163.com.
  • Wang JZ; Tengchong County Center for Disease Control and Prevention, Tengchong, 679100, China. tcwangjiazhi@yahoo.com.cn.
  • Li CF; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. lichunfu@
  • Wang HY; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. wanghengy
  • Nie RH; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. nrh912@yi
  • Guo XR; Yangjiang County Center for Disease Control and Prevention, Yingjiang, 679300, China. xiaoduorong@vip.qq.com.
  • Lin YX; Yangjiang County Center for Disease Control and Prevention, Yingjiang, 679300, China. yjjkzx@163.com.
  • Li M; National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, PR China. li_mei76@163.com.
  • Wang J; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. wj5369609
  • Xu JW; Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer, 665000, China. xjw426@16
Malar J ; 14: 47, 2015 Feb 05.
Article em En | MEDLINE | ID: mdl-25652213
BACKGROUND: Artemisinin-based combination therapy (ACT) is the recommended first-line treatment of falciparum malaria in all endemic countries. Artemisinin resistance in Plasmodium falciparum has been confirmed in the Greater Mekong subregion (GMS). Dihydroartemisinin-piperaquine (DAPQ) is the most commonly used ACT in China. To understand the DAPQ sensitivity of P. falciparum, DAPQ resistance was monitored in vivo along the China-Myanmar border from 2007 to 2013. METHODS: Eligible patients with mono-infections of P. falciparum were recruited to this study after obtaining full informed consent. DAPQ tablets for different categories of kg body weight ranges were given once a day for three days. Patients were followed up for 42 days. Polymerase chain reaction (PCR) was conducted to distinguish between re-infection and recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome was assessed according to the WHO recommended standards. RESULTS: 243 patients were completed valid follow-up. The fever clearance time (FCT) and asexual parasite clearance times (APCT) were, respectively, 36.5 ± 10.9 and 43.5 ± 11.8 hours, and there was an increasing trend of both FCT (F = 268.41, P < 0.0001) and APCT (F = 88.6, P < 0.0001) from 2007 to 2013. Eight (3.3%, 95% confidence interval, 1.4-6.4%) patients present parasitaemia on day three after medication; however they were spontaneous cure on day four. 241 (99.2%; 95% CI, 97.1-99.9%) of the patients were adequate clinical and parasitological response (ACPR) and the proportions of ACPR had not changed significantly from 2007 to 2013 (X(2) = 2.81, P = 0.7288). CONCLUSION: In terms of efficacy, DAPQ is still an effective treatment for falciparum malaria. DAPQ sensitivity in P. falciparum had not significantly changed along the China-Myanmar border of Yunnan Province, China. However more attentions should be given to becoming slower fever and parasite clearance.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Quinolinas / Malária Falciparum / Artemisininas / Antimaláricos Tipo de estudo: Diagnostic_studies / Guideline Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Quinolinas / Malária Falciparum / Artemisininas / Antimaláricos Tipo de estudo: Diagnostic_studies / Guideline Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2015 Tipo de documento: Article